ArticleCanadian liver journal2024
Severe acute allograft rejection 22 years after liver transplantation.
Article in Canadian liver journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early acute cellular rejection occurs commonly within the first month after liver transplantation, is easily reversible with treatment, and has little impact on long-term graft survival. In contrast, late allograft rejection, typically defined as occurring after 3-6 months post-transplantation, can lead to the development of chronic rejection and graft loss. Alloreactivity and the risk of rejection decreases with time, since transplantation and many long-term liver transplant recipients can maintain graft function with minimal immunosuppression. We describe a case of acute allograft rejection 22 years and 5 months after liver transplantation. The patient, transplanted for biliary atresia as a young child, had three prior episodes of allograft rejection: two within the first month of transplantation, and one 4 years after. Subsequent to this, she had normal liver biochemistry and was maintained on minimal immunosuppression for many years. Following a diagnosis of immune thrombocytopenic purpura and marginal zone lymphoma, she was switched from tacrolimus to mycophenolate monotherapy, and subsequently developed significantly elevated liver enzymes, and biopsy confirmed severe acute allograft rejection. Our experience demonstrates that despite the liver being an immunotolerant organ, which often can be maintained with minimal immunosuppression post-transplantation, acute allograft rejection can occur at any stage and should always be considered as a possible cause of liver biochemistry abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.